链霉亲和素亲和网格制备用于冷冻电子显微镜样品制备
2023年12月29日
7.5K 次观看
提供了用于制备链霉亲和素亲和力网格的分步方案，用于通过冷冻电子显微镜对具有挑战性的大分子样品进行结构研究。
冷冻电镜最近取得了许多技术进步，包括显微镜硬件本身的进步，提高了图像的整体质量，以及用于处理冷冻电镜图像的软件的发展，这些软件可以开始处理许多样品中存在的大量异质性。样品制备仍然是冷冻电镜中最大的瓶颈之一。样品量可能有限，蛋白质在玻璃化过程中往往会吸收到疏水性空气-水界面。
这可能导致样品变性、较大蛋白质复合物的分解以及冷冻电镜图像中存在的优选颗粒取向。这些网格利用链霉亲和素和生物素之间的高亲和力相互作用来束缚生物素化样品并保护它们免受疏水性空气-水界面的影响。我们可以使用非常低的样品量，样品的随机生物素兴高采烈提供了一种策略，可以克服使用其他支撑层时可能观察到的优先取向问题。
概述
本文介绍了一种详细的制备链霉亲和网格的协议，这对于使用冷冻电子显微镜（cryo-EM）进行具有挑战性的大分子样品的结构研究至关重要。该方法解决了样品制备中常见的问题，如蛋白质变性和取向偏差。
关键研究组成部分
科学领域
- 冷冻电子显微镜
- 结构生物学
- 大分子分析
背景
- 冷冻电子显微镜技术的最新进展提高了图像质量。
- 样品制备是冷冻电子显微镜工作流程中的一个重要瓶颈。
- 蛋白质在样品制备过程中可能发生变性或优先取向。
- 链霉亲和素-生物素相互作用可以稳定样品并缓解这些问题。
研究目的
- 提供一个可靠的制备链霉亲和网格的协议。
- 通过减少样品变性来提高冷冻电子显微镜图像的质量。
- 解决冷冻电子显微镜样品中的优先取向问题。
使用的方法
- 用乙醇和氯仿清洁和准备玻璃注射器和网格。
- 创建脂质单层以稳定生物素化样品。
- 用链霉亲和素孵育网格并冲洗以去除未结合的蛋白质。
- 使用碳蒸发来准备网格进行成像。
主要结果
- 该协议成功制备了维持样品完整性的网格。
- 显微镜图像显示了连续的网格图案，表明有效的晶格形成。
- 快速傅里叶变换分析确认了链霉亲和素信号的去除。
- 该方法允许使用低样品量而不影响质量。
结论
- 链霉亲和网格协议对冷冻电子显微镜研究有效。
- 这种方法可以显著改善具有挑战性的大分子样品的分析。
- 未来的应用可能进一步增强结构生物学研究。
常见问题
使用链霉亲和网格的主要优势是什么？
它们稳定了生物素化样品并减少了与样品变性和取向相关的问题。
这个协议如何改善冷冻电子显微镜图像质量？
通过在制备过程中最小化样品变性和优先取向。
制备网格的关键步骤是什么？
清洁注射器和网格，创建脂质单层，并用链霉亲和素孵育。
这种方法可以用低样品量吗？
可以，该协议设计为在非常低的样品量下有效工作。
成功制备网格的确认是什么？
显微镜图像和快速傅里叶变换分析确认了有效的晶格形成。
这种方法是否适用于所有大分子样品？
它对易于变性的具有挑战性的样品特别有益。
Executive Industry Relevance
Streptavidin-affinity grid fabrication addresses persistent bottlenecks in cryo-EM sample preparation, enabling high-fidelity structural analysis of macromolecules with limited sample availability. By mitigating denaturation and orientation artifacts at the air-water interface, this method enhances predictive confidence in early discovery and structural biology pipelines. Its robust protocol supports enterprise-wide adoption for challenging targets and complex assemblies.
Strategic Applications in Biopharma R&D
Early Discovery & Target Validation
- Enables structural interrogation of low-abundance or fragile protein complexes.
- Reduces mechanistic ambiguity by preserving native conformations during vitrification.
- Supports functional target validation through improved sample integrity.
- Facilitates portfolio triage by providing reliable structural data for difficult targets.
Screening & Assay Development
- Prepares validated cryo-EM grids for downstream high-throughput imaging workflows.
- Improves assay reproducibility by minimizing sample loss and orientation bias.
- Supports quantitative structural readouts essential for compound evaluation.
- Enables platform reuse for diverse biotinylated targets and complexes.
Translational & Preclinical Research
- Aligns structural data with disease-relevant biomolecular assemblies when applicable.
- Ensures continuity from discovery-stage characterization to preclinical validation.
- De-risks translational advancement by confirming molecular integrity under cryo-EM conditions.
- Supports risk-adjusted decision-making for complex biologics and modalities.
Pipeline & Workflow Integration
This fabrication protocol integrates at the interface of sample preparation and structural analysis, bridging early discovery and lead identification stages for structurally challenging targets.
- Discovery Biology: Provides a platform for hypothesis testing and pathway clarification via high-resolution imaging.
- Screening: Delivers reproducible, quantitative grid preparation for reliable downstream analysis.
- Analytics: Enables robust measurement of lattice formation and sample integrity through micrograph and FFT analysis.
- Translational Research: Facilitates preclinical continuity by supporting structural studies of disease-relevant complexes.
- Enterprise Reuse: Offers a standardized, reusable workflow for biotinylated sample preparation across programs.
Operational & Enterprise Impact
- Scientific Value: Increases predictive confidence and reduces mechanistic risk in structural studies.
- Operational Value: Standardizes grid preparation, improving reproducibility and scalability across teams.
- Strategic Value: Enables better go/no-go decisions by providing reliable data for challenging targets.
- Portfolio Impact: Supports risk-adjusted prioritization and advancement of structurally complex assets.
Implementation Considerations
- Requires technical expertise in cryo-EM grid handling and biotinylation chemistry.
- Demands access to specialized instrumentation for grid fabrication and carbon evaporation.
- Benefits from cross-team standardization to ensure reproducibility and troubleshooting support.
- Adaptable to various biotinylated proteins and complexes, but may require optimization for new targets.
- Limited commercial availability necessitates in-house protocol adoption and training.
Biopharma FAQs
Why does null hypothesis testing matter for streptavidin grid validation?
Null hypothesis testing ensures that observed improvements in sample integrity and orientation are statistically significant, supporting robust target validation in cryo-EM workflows.
How does independent variable isolation fit in grid fabrication?
Isolating variables such as biotinylation efficiency and incubation conditions clarifies their impact on lattice formation, streamlining discovery-stage optimization and reproducibility.
What do quantitative dependent variable measurements enable in this protocol?
Quantitative analysis of micrograph patterns and FFT results enables objective assessment of grid quality, supporting data-driven advancement decisions in structural biology pipelines.
Why are replication requirements critical for cross-functional cryo-EM teams?
Replication ensures that grid fabrication outcomes are consistent across operators and sites, facilitating reliable collaboration and enterprise-wide adoption of the protocol.
What statistical analysis capabilities are needed before grid implementation?
Teams require statistical tools to evaluate lattice formation, sample preservation, and orientation distributions, ensuring readiness for high-confidence structural studies.
